Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus (CHIKV) vaccine in adolescents. The trial demonstrated a ‘sustained ...

In November, the U.S. FDA approved Ixchiq as the world’s first chikungunya vaccine. The company reported 28-day and six-month data from the VLA1553-321 trial in 2023 and 2024, respectively.

(RTTNews) - Valneva SE (VALN) a specialty vaccine company, on Wednesday announced that it is advancing to a Phase 3 trial for IXCHIQ, its single-dose chikungunya vaccine, in children aged 1 to 11 ...

Ixchiq is now the first vaccine approved in the UK to prevent disease caused by the chikungunya virus (CHIKV) in individuals aged 18 years and older. CHIKV is a mosquito-borne viral disease that ...

IXCHIQ ®, in 304 children. Partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union, the trial is intended to support a pivotal Phase 3 ...

Accordingly, the single-shot vaccine branded as Ixchiq will be indicated in the U.K. for those 18 years and older to prevent chikungunya, a mosquito-borne disease caused by the chikungunya virus.

For investors’ note, IXCHIQ is the world’s first and only licensed chikungunya vaccine available to address this significant unmet medical need. The trial data supports and strengthens the ...

Saint Herblain (France), February 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory ...

Valneva (NASDAQ:VALN) ADRs traded higher in the premarket on Tuesday after the French biotech posted additional data for its FDA-approved chikungunya vaccine, Ixchiq, from a Phase 3 trial for ...

The approval is based on IXCHIQ ® ’s final pivotal Phase 3 data, published in The Lancet, which included more than 4,000 participants and demonstrated that a single dose of the live-attenuated ...